Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 1.00 |
| ▸ | RAB9A | P51151 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 2/20 | 1.00 |
| ▸ | KDR | P35968 | 1/20 | 1.00 |
| ▸ | FLT3 | P36888 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | GLA | P06280 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.68 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.60 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.54 |
| ▸ | NQO2 | P16083 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14532728 | 0.89 | NPC1 (0.79) | NPC1RAB9ASMN1; SMN2PDGFRBKDR | |
| SCHEMBL29184272 | 0.85 | NPC1 (0.74) | NPC1RAB9ASMN1; SMN2PDGFRBKDR | |
| SCHEMBL30846532 | 0.85 | NPC1 (0.74) | NPC1RAB9ASMN1; SMN2PDGFRBKDR | |
| SCHEMBL6215142 | 0.85 | NPC1 (0.73) | NPC1RAB9ASMN1; SMN2PDGFRBKDR | |
| SCHEMBL13541764 | 0.82 | NPC1 (0.70) | NPC1RAB9ASMN1; SMN2PDGFRBKDR | |
| SCHEMBL8499222 | 0.82 | NPC1 (0.70) | NPC1RAB9ASMN1; SMN2PDGFRBKDR | |
| SCHEMBL16687607 | 0.82 | NPC1 (0.70) | NPC1RAB9ASMN1; SMN2PDGFRBKDR | |
| SCHEMBL30846535 | 0.82 | NPC1 (0.70) | NPC1RAB9ASMN1; SMN2PDGFRBKDR | |
| SCHEMBL8499923 | 0.81 | SMN1; SMN2 (0.69) | NPC1RAB9ASMN1; SMN2PDGFRBKDR | |
| SCHEMBL29351353 | 0.81 | SMN1; SMN2 (1.00) | NPC1RAB9ASMN1; SMN2PDGFRBKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 239 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027230-A1 | DRUG DELIVERY SYSTEM, TREATMENT KIT, AND METHOD FOR INHIBITING PROLIFERATION OR METASTASIS OF CANCER CELL | CHINA MEDICAL UNIVERSITY (TW) | 2026-01-29 | — | — | US | claimed |
| EP-4572781-A2 | SYNERGISTIC INTERACTIONS FOR IMPROVED CANCER TREATMENT | The United States of America, as Represented By the Secretary, Department of Health and Human Services (US) | 2025-06-25 | — | — | EP | claimed |
| US-20250161293-A1 | CRENOLANIB FOR TREATING FLT3 MUTATED PROLIFERATIVE DISORDERS RELAPSED/REFRACTORY TO PRIOR TREATMENT | AROG PHARMACEUTICALS, INC. | 2025-05-22 | — | — | US | claimed |
| US-12295948-B2 | Crenolanib for treating FLT3 mutated proliferative disorders relapsed/refractory to prior treatment | AROG PHARMACEUTICALS, INC. (US) | 2025-05-13 | — | — | US | claimed |
| WO-2024173833-A1 | COMBINATION OF A CDK INHIBITOR AND A FLT3 INHIBITOR FOR THE TREATMENT OF CANCER | MEI PHARMA, INC. (US) | 2024-08-22 | — | — | WO | claimed |
| US-20240165199-A1 | PROX1 PREVENTS MYXOMATOUS VALVE DISEASE BY INHIBITING PDGF-B SIGNALING | OKLAHOMA MEDICAL RESEARCH FOUNDATION | 2024-05-23 | — | — | US | claimed |
| US-20240100040-A1 | CRENOLANIB FOR TREATING FLT3 MUTATED PROLIFERATIVE DISORDERS RELAPSED/REFRACTORY TO PRIOR TREATMENT | AROG PHARMACEUTICALS, INC. | 2024-03-28 | — | — | US | claimed |
| WO-2024040132-A2 | SYNERGISTIC INTERACTIONS FOR IMPROVED CANCER TREATMENT | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (US) | 2024-02-22 | — | — | WO | claimed |
| US-11857546-B2 | Crenolanib for treating FLT3 mutated proliferative disorders relapsed/refractory to prior treatment | AROG PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | claimed |
| US-20230128591-A1 | CRENOLANIB FOR TREATING FLT3 MUTATED PROLIFERATIVE DISORDERS RELAPSED/REFRACTORY TO PRIOR TREATMENT | AROG PHARMACEUTICALS, INC. | 2023-04-27 | — | — | US | claimed |
| WO-2005051229-A2 | DEVICES DELIVERING THERAPEUTIC AGENTS AND METHODS REGARDING THE SAME | AVANTEC VASCULAR CORPORATION (US) | 2005-06-09 | — | — | WO | claimed |
| US-20050125054-A1 | Devices delivering therapeutic agents and methods regarding the same | AVANTEC VASCULAR CORPORATION (US) | 2005-06-09 | — | — | US | claimed |
| WO-2004010900-A1 | DEVICES DELIVERING THERAPEUTIC AGENTS AND METHODS REGARDING THE SAME | AVANTEC VASCULAR CORPORATION (US) | 2004-02-05 | — | — | WO | claimed |
| US-RE36256-E | ADMINISTERING ARYL-SUBSTITUTED QUINOXALINE DERIVATIVES AS ANTIPROLIFERATIVE, ANTICARCINOGENIC AND ANTITUMOR AGENTS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-07-20 | — | — | US | claimed |
| EP-0584222-B1 | BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE | RHONE POULENC RORER INT (US) | 1997-10-08 | — | — | EP | claimed |
| US-5646153-A | INHIBITING ABNORMAL CELL PROLIFERATION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-07-08 | — | — | US | claimed |
| US-5480883-A | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-01-02 | — | — | US | claimed |
| EP-0584222-A4 | BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE | RHONE POULENC RORER INT (US) | 1994-07-06 | — | — | EP | claimed |
| EP-0584222-A1 | BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE. | RHONE POULENC RORER INT (US) | 1994-03-02 | — | — | EP | claimed |
| WO-1992020642-A1 | BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1992-11-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027230-A1 | DRUG DELIVERY SYSTEM, TREATMENT KIT, AND METHOD FOR INHIBITING PROLIFERATION OR METASTASIS OF CANCER CELL | LDLR, NPC1L1, LPXN | NPC1 16/4885RAB9A 3226/4885SMN1; SMN2 2481/4885 |
| US-11857546-B2 | Crenolanib for treating FLT3 mutated proliferative disorders relapsed/refractory to prior treatment | FLT3, RET, MKI67 | NPC1 3832/4885RAB9A 2829/4885SMN1; SMN2 3436/4885 |
| US-12295948-B2 | Crenolanib for treating FLT3 mutated proliferative disorders relapsed/refractory to prior treatment | FLT3, RET, MKI67 | NPC1 3832/4885RAB9A 2829/4885SMN1; SMN2 3436/4885 |
| US-20230128591-A1 | CRENOLANIB FOR TREATING FLT3 MUTATED PROLIFERATIVE DISORDERS RELAPSED/REFRACTORY TO PRIOR TREATMENT | FLT3, RET, MKI67 | NPC1 3832/4885RAB9A 2829/4885SMN1; SMN2 3436/4885 |
| US-20250161293-A1 | CRENOLANIB FOR TREATING FLT3 MUTATED PROLIFERATIVE DISORDERS RELAPSED/REFRACTORY TO PRIOR TREATMENT | FLT3, RET, MKI67 | NPC1 3832/4885RAB9A 2829/4885SMN1; SMN2 3436/4885 |
| US-20240100040-A1 | CRENOLANIB FOR TREATING FLT3 MUTATED PROLIFERATIVE DISORDERS RELAPSED/REFRACTORY TO PRIOR TREATMENT | FLT3, RET, MKI67 | NPC1 3832/4885RAB9A 2829/4885SMN1; SMN2 3436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.